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Abstract: Lysophosphatidic acid (LPA) is the umbrella term for lipid signaling molecules 
that share structural homology and activate the family of LPA receptors. Farnesyl 
Pyrophosphate (FPP) is commonly known as an intermediate in the synthesis of steroid 
hormones; however, its function as a signaling lipid is beginning to be explored. FPP was 
recently shown to an activator of the G-protein coupled receptor 92 (also known as LPA5) 
of the calcium channel TRPV3. The LPA receptors (including GPR92) are associated with 
the signal transduction of noxious stimuli, however, very little is known about the 
distribution of their signaling ligands (LPAs and FPP) in the brain. Here, using 
HPLC/MS/MS, we developed extraction and analytical methods for measuring levels of 
FPP and 4 species of LPA (palmitoyl, stearoyl, oleoyl and arachidonoyl-sn-glycerol-3 
phosphate) in rodent brain. Relative distributions of each of the five compounds was 
significantly different across the brain suggesting divergent functionality for each as 
signaling molecules based on where and how much of each is being produced. Brainstem, 
midbrain, and thalamus contained the highest levels measured for each compound, though 
none in the same ratios while relatively small amounts were produced in cortex and 
cerebellum. These data provide a framework for investigations into functional relationships 
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of these lipid ligands in specific brain areas, many of which are associated with the 
perception of pain. 
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1. Introduction 
Lysophosphatidic acid (LPA) is not a single molecule, but a collection of signaling molecules that 
share structural homology and activate the family of LPA receptors. LPAs are structurally composed 
of a fatty acid linked to sn-glycerol-3 phosphate (e.g., arachidonoyl-sn-glycerol-3 phosphate). They 
induce their effects through binding to members of the superfamily of G protein-coupled receptors 
(GPCRs) including LPA1 (also named VZG-1, MREC1.3 or EDG-2) [1,2], LPA2 (or EDG-4) [3], 
LPA3 (or EDG-7) [4,5], LPA4 (formerly GPR23) [6] and more recently discovered LPA5 (formerly 
GPR92) [7]. These receptors couple to at least three different types of G proteins, notably Gq/11, Gi/o 
and G12/13 [8]. LPA receptors coupled to Gi proteins drive the activation of the PI3K-Akt pathway [9], 
whereas, LPA receptors bound to G12/13 activate the small GTPase RhoA [10]. LPA ligands have been 
known to influence a wide range of cellular functions including cell proliferation, apoptosis, and 
migration [9,11,12]. Overwhelming evidence points to the function of LPA in pain because LPA  
(1) stimulates cyclooxygenase-2 expression (COX-2) [13], which contributes to inflammatory pain;  
(2) increases reactive oxygen species (ROS) release [14], which is involved in the development and 
maintenance of neuropathic pain [15]; (3) induces nociception-producing activity and substance P 
release on sensory neurons [16]; and (4) is involved in the initiation of neuropathic pain [3,17,18] 
Farnesyl pyrophosphate (FPP) is a key intermediate in the biosynthesis of steroids including 
cholesterol as well as the donor of the farnesyl group for isoprenylation of many proteins, including 
the βγ subunit of some G proteins and GTPases, Ras and Rho [19]. FPP is synthesized from farnesol 
via two successive phosphorylation reactions mediated by farnesol kinase and farnesyl phosphate 
kinase, transitioning first through farnesyl monophosphate (FMP) then to FPP [20].  
The actions of a class of cholesterol-lowering drugs called Statins (e.g., Atorvastatin, Lipitor) 
suggest the impact of FPP on pain. These drugs inhibit HMG-CoA reductase (3-hydroxsyl-3-
methylglutaryl coenzyme A reductase), the first committed enzyme of the cholesterol synthesis 
pathway [21]. Recent data indicate that Statins are also anti-inflammatory and anti-nociceptive 
compounds [22]. This report also showed that Atorvastatin lowers hyperalgesia produced by 
bradykinin and cytokines as well as being associated with a drop in inflammatory mediators such as 
TNF-α and IL-1β. Because FPP is a key intermediate for cholesterol synthesis, a reduced level of such 
intermediates may contribute to reduced hyperalgesia. 
Recent data indicated that FPP acts as a ligand of GPR92/LPA5 [23], suggesting an underlying 
mechanism for FPP in relation to pain. Activation of GPR92/LPA5 by FPP increases IP production, 
cAMP levels, and Ca
2+ levels in a concentration-dependent manner. Oh and colleagues further 
demonstrated that FPP and LPA are able to activate Gq/11 and Gs-mediate signaling pathways. Evidence 
for a role in pain comes from the fact that GPCR92/LPA5 is highly expressed in and largely co-
localized with TRPV1 in mouse and human dorsal root ganglion [23], suggesting that this receptor Int. J. Mol. Sci. 2010, 11                 
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may contribute to the processing of noxious sensory stimuli. However, FPP may not interact with 
GPR92 in a typical receptor-ligand manner. A report by Yin and colleagues [24] states that FPP was 
not effective in recruiting beta arrestin in a GPR92 expression system. A more recent report shows that 
FPP is also a potent activator of TPRV3, which adds yet another dimension on how FPP may play a 
role in the processing of noxious stimuli [25]. It will be important to investigate any potential 
interactions of GPR92/LPA5 with TRPV3 to further elucidate this complex signaling system.  
In order to begin investigations of FPP and LPA’s functional relevance as signaling molecules in 
the central nervous system, we developed HPLC/MS/MS extraction protocols for each compound from 
brain tissue and examined the relative distribution of FPP and four different endogenous LPAs;   
oleoyl-LPA (O-LPA), arachidonyl-LPA (A-LPA), palmitoyl-LPA (P-LPA) and stearoyl-LPA (S-LPA) 
were measured here in 9 distinct regions of the brain. Our findings show there is not a uniform 
distribution throughout the brain of any of the 5 compounds measured lending support to the 
hypothesis that they are working as signaling molecules and not simply as structural lipids. While the 
relative distributions are not the same, the highest concentrations of each are found primarily in 
brainstem and midbrain providing a focus for future research.  
2. Results and Discussion 
2.1. Distribution of FPP in Rat Brain 
Co-eluting peaks for synthesized FPP and a brain constituent that matched the HPLC/MS/MS 
fingerprint of FPP were observed in each area of the brain examined (representative brain region 
shown in Figure 1). The average rate of recoveries across brain areas was 59%. FPP was not 
distributed equally throughout the brain (Figure 1). The highest production of FPP was measured in the 
brainstem (89.55E-12 ± 17.10E-12 moles/gram tissue), followed by the midbrain   
(56.95E-12 ± 19.89E-12) and thalamus (64.95E-12 ± 15.20E-12), moderate levels were measured in 
the hypothalamus (39.91E-12 ± 6.8E-12), cerebellum (33.62E-12 ± 8.94E-12), hippocampus   
(37.31E-12 ± 4.98E-12) and striatum (45.19E-12 ± 12.51E-12), and the lowest levels were measured 
in the pituitary (11.81E-12 ± 4.81E-12) and cortex (23.09E-12 ± 6.78E-12).  
Figure 1. (A) structure of FPP (B) co-eluting peaks for synthesized FPP (standard FPP) 
and a representative brain constituent (Endogenous FPP) (C) distribution of FPP in 
selective brain areas. Abbreviations: PIT, pituitary; CTX, cortex; CER, cerebellum; HIPP, 
hippocampus; HYP, hypothalamus; STR, striatum; MB, midbrain; THAL, thalamus; BS, 
brain stem. 
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Figure 1. Cont. 
 
 
2.2. Distribution of Four LPA Species in Rat Brain 
Co-eluting peaks for all four synthesized LPA molecules and a corresponding brain constituent 
were observed in each area of the brain examined. Figure 2 demonstrates the chromatograms of the 
LPAs HPLC/MS/MS methods in which each LPA species is measured from the complex brain lipid 
extract. Using the C18 reversed-phased analytical column the arachidonoyl species elutes first, 
followed by the palmitoyl, oleoyl and finally stearoyl species.  
Like FPP, the highest amounts of LPAs were measured in the brainstem, midbrain, and thalamus, 
though not equally distributed (Table 1). Relative abundance of each LPA species was not consistent 
in any brain areas tested (Table 1). A-LPA shows the most divergence from the other three LPA 
species in that it is least abundant in cortex and the levels in the hypothalamus are equivalent to those 
in the brainstem. Averaged recoveries were equivalent across compounds: A-LPA (90 ± 6%), O-LPA 
(70 ± 17%), P-LPA (70 ± 23%), and S-LPA (65 ± 8%).  Int. J. Mol. Sci. 2010, 11                 
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Figure 2. Structure of four LPA species and corresponding HPLC/MS/MS 
chromatographs for each of these species from brain extracts. Colors for each 
chromatographic peak correspond to the color bar next to the name of the LPA. Using the 
C18 reversed phase analytical column the least saturated LPA (arachidonoyl-sn-glycerol-3 
phosphate) elutes first and the longest and completely saturated LPA (stearoyl-sn-glycerol-3 
phosphate) elutes last.  
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Table 1. Levels of 4 LPA species in 8 areas of the rat brain determined by HPLC/MS/MS. 
Amounts are listed in acceding order by brain area. 
P-LPA in nmols/gr   A-LPA in pmols/gr  
Hypothalamus  4.22 ± 0.81  Cortex  220 ± 30.2 
Hippocampus  6.16 ± 0.37  Cerebellum  285 ± 25.1 
Cortex  6.96 ± 1.19  Striatum  299 ± 23.2 
Striatum  7.88 ± 1.11  Hippocampus  316 ± 15.3 
Cerebellum  13.4 ± 1.58  Hypothalamus  339 ± 67.6 
Thalamus  19.6 ± 0.58  Brain Stem  364 ± 16.3 
Brain Stem  25 ± 3.17  Thalamus  478 ± 29.6 
Midbrain  28.6 ± 2.26  Midbrain  536 ± 41.8 
S-LPA in nmols/gr   O-LPA in nmols/gr 
Hypothalamus  4.34 ± 1.64  Hypothalamus  7.58 ± 1.83 
Hippocampus  6.30 ± 0.62  Hippocampus  9.76 ± 1.22 
Striatum  7.68 ± 0.46  Striatum  11.4 ± 1.01 
Cortex  10.7 ± 0.55  Cortex  17.5 ± 3.27 
Cerebellum  11.2 ± 0.51  Thalamus  37.8 ± 4.05 
Brain Stem  13 ± 0.56  Cerebellum  28.1 ± 5.34 
Midbrain  14 ± 1.99  Midbrain  63.6 ± 7.48 
Thalamus  15.7 ± 2.24  Brain Stem  69.5 ± 4.30 
2.3. Discussion 
This study provides a framework to examine FPP and LPA production that will direct future studies 
on functional relevance of each as signaling molecules. This is particularly important in that these data 
show that the relative distributions are significantly different and, therefore, their contributions as 
substrates and signaling molecules is dependent on the population and phenotype of cells within a 
region. That there is not an equal distribution throughout the brain also provides evidence to suggest 
that the use of plasma levels of these lipids is an inadequate method for measuring central nervous 
system activity. While these lipids are detectable in plasma, it is important to recognize the distinction 
between those derived likely from circulating immune cells and those that are made on demand within 
a specific region of the CNS.  
The highest levels of FPP, A-LPA, O-LPA and P-LPA were detected in the brain stem and 
midbrain in our study. Interestingly, these areas overlap with the descending modulatory system for 
pain. Rostral ventromedial medullar (RVM) in the brainstem was established as an integral relay in the 
descending modulation of pain [26,27]. Additionally, the periaqueductal gray (PAG) has extensive 
involvement in the descending inhibition of pain and is a rich area of study for both opioid [26] and 
cannabinoid analgesia [28,29].  
Electrical stimulation in the lateral and medial midbrain PAG and intraplantar formalin injection 
caused significant increases in the production of the endogenous cannabinoid anandamide in the PAG 
[29]. Acute stress was also shown to suppress pain by increasing the production of the 
endocannabinoids 2-AG and anandamide in the PAG region, which are known to be associated with 
stress-induced analgesia [28]. In the same study there was a relationship with the elevation of Int. J. Mol. Sci. 2010, 11                 
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endocannabinoid levels in the PAG after injection of inhibitors of endocannabinoid degradation 
enzymes and an increase in tolerance to noxious stimuli. Here we show that FPP and LPA are 
significantly more abundant in the midbrain and brainstem. Their abundance here may be an indication 
that they are involved in the descending regulatory pathways for pain including the PAG and the RVM, 
providing yet another aspect of the fine-tuning of the PAG and RVM systems.  
By examining the relative levels of these lipids in distinct brain regions we also demonstrate that 
they are not merely structural components of the cell membrane. If they were simply produced in this 
capacity their levels should be more consistent throughout the brain. Even with the growing interest in 
LPAs and FPP as signaling molecules over the last decade, few studies have examined levels of these 
lipids in the CNS. One study measured the level of FPP using LC/MS/MS in human frontal cortex 
tissue [30] from post-mortem brains in five elderly patients and found it to be in the range of   
4.5 ng/mg. Here, we show that levels of FPP in rat cortex are ~7 ng/mg, so these levels are in an 
equivalent range.  
A current therapy aimed at the reduction of lipogensis related to high blood pressure and heart 
disease is the use of Statins. These are already known to reduce hypernociception likely mediated by 
changes in the levels of bradykinin and cytokines, IL-1β, and PGE2 [22]. However, the antinociceptive 
effect of Statins also appears to be tightly related to reducing the production of FPP in that exogenous 
malvonate, the precursor of FPP, reversed the antinociception by Statins in the same study. Also, 
inhibition of isoprenoid production by Statins has been shown to increase NOS expression which 
prevents hypernociceptive activity [31]. Although Statins do not cross the blood brain barrier [32], the 
peripheral action of statins may reduce central sensitization by decreasing peripheral nociceptive input 
to the central nervous system [33]. Along with HMG CoA reductase, bisphosphonate is also known to 
decrease FPP levels primarily by inhibiting farnesyl diphosphate synthase (FPPS) [34]. Interestingly, 
bisphosphanate also has antinociceptive effects [35] in that chronic treatment with bisphosphanate 
attenuated hyperalgesia associated with chronic peripheral neuropathy and inflammation.  
The roles of LPAs in pain are also currently under intense study and have been recently reviewed 
by many authors [36,37]. LPA causes reactive oxygen species (ROS) release [38], which is involved in 
signaling of noxious stimuli and the perception of pain [39,40]. LPA-induced activation of 
phosphatidylinositol–3 kinase (PI3K) has been suggested to play an essential role in the induction of 
pain hypersensitivity [41]. PI3K is involved in capsaicin-induced heat hyperalgesia, perhaps through 
TRPV1 sensitization in that capsaicin-induced TRPV1 current enhancement was blocked by PI3K 
inhibition. LPA was also shown to cause sensory neuron sensitization through Gi/0 activation and 
substance P (SP) release [42]. Substance P directly activates IL-8 release from macrophages leading to 
hyperalgesia through sympathetic neurons stimulation [43,44]. Moreover, Inoue M. et al. showed that 
intrathecal injection of LPA into wild-type animals elicited mechanical allodynia and thermal 
hyperalgesia effects similar to those induced by peripheral nerve injury [18]. These effects of LPAs on 
peripheral sensory processing underscore their potency and the need to understand LPA functions in 
the CNS.  
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3. Experimental Section 
3.1. Sample Preparation 
Hypothalamus, pituitary, thalamus, brainstem, cerebellum, hippocampus, striatum, cortex and 
midbrain were dissected from 10 female Sprague-Dawley rats and immediately frozen at -80 °C until 
used for extractions. For FPP extractions, tissue was homogenized on ice in an ethanol/butanol/70 mM 
(1:1.25:1.25. v/v/v) ammonium hydroxide solution using a polytron homogenizer. The homogenate 
was centrifuged at 20,000 g, 25 °C for 5 min. The supernatant was loaded on polymeric solid phase 
extraction columns (Strata-X SPE, Phenomena), washed with 40% HPLC methanol and eluted with 
100% HPLC methanol/1% triethyl amine. For LPA extractions, tissue was homogenized in 100% 
HPLC-grade methanol, homogenate was centrifuged at 20,000 g, 25 °C for 20 min, the supernatant 
then diluted with HPLC-grade water to make a 30% organic solution which was then loaded on   
pre-conditioned Empore C8 SPE columns (Varian, Palo Alto, CA), columns were washed with   
HPLC-grade water, 40% HPLC-grade methanol, and eluted with 100% HPLC-grade methanol.  
3.2. HPLC/MS/MS 
Levels of each compound were analyzed by multiple reactions monitoring (MRM) mode on a triple 
quadrupole mass spectrometer API 3000, with electrospray ionization. Samples were loaded using 
Shimadzu SCL10Avp autosampler. The flow rate was 200 uL/min achieved by a system comprised of 
a Shimadzu controller and two Shimadzu LC10ADvp pumps. 
3.2.1. FPP Analysis 
The chromatographic analysis was performed on a C18 reversed phase column (Phenomenex 
Gemini C18 column, 50 × 2.0 mm, 3 µM) guarded by SecurityGuard Cartridge System (Phenomenex). 
Mobile phase A, 1.0% triethyl amine (TEA), and mobile phase B, 90% isopropanol with 1.0% TEA, 
were used for gradient elution. Mobile phase B was held constant at 2% for 2 min (mobile phase A at 
98%) after sample injection, then a linear gradient increased B to 100% between 2 and 12 min, which 
was maintained for 2 min and brought back to 2% at 14.50 prior to 2 minutes of column equilibration. 
Columns were maintained at 40 °C. Recoveries were determined by spiking supernatant from paired 
brain areas and analyzing the% recovery of the spiked samples. FPP levels were determined using 
MRM in negative ion mode where the parent mass (MH-) was 381.0 m/z and the two product ions 
measured where 79.0 and 158.8 m/z. 
3.2.2. LPA Analysis 
The chromatographic analysis was performed on a 210 mm Zorbax Eclipse XDB-C18 reversed 
phase HPLC (3.5 um internal diameter) column maintained at 40 °C. Mobile phase A:   
80/20 H2O/MeOH with 10mM ammonium acetate and 1% acetic acid and mobile phase B: 100% 
Methanol with 10mM ammonium acetate and 1% acetic acid were used for gradient loading and 
elution. LPA parent and fragment masses monitored via MRM are as follows: P-LPA parent mass 
409.48 fragment mass 153.10; O-LPA parent mass 435.57 fragment mass 153.10; S-LPA parent mass Int. J. Mol. Sci. 2010, 11                 
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437.27 fragment mass 153.10; and A-LPA parent mass 457.30 fragment mass 153.10. Due to a lack of 
deuterium-labeled standards to use as internal standards to calculate percent recoveries, they were 
determined by using the alternate half of the brain dissections from those used for extractions of 
unknown amounts and spiking brain areas with µM quantities of each LPA subtype to estimate overall 
recoveries.  
4. Conclusions 
In this study, levels of FPP and four species of LPA were shown to be differentially produced 
throughout the rodent brain. These data provide a framework for investigations into the functional 
relationships of these lipid ligands in these specific brain areas, many of which are associated   
with pain.  
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